https://www.live-feeds.com/feed/the-blowout-and-bull-case-news-that-sent-two-biotechs-flyingContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/the-blowout-and-bull-case-news-that-sent-two-biotechs-flyinghttps://www.live-feeds.com/feed/the-blowout-and-bull-case-news-that-sent-two-biotechs-flying#u63477Thu, 10 Sep 2026 04:02:23 +0000Roivant has achieved its goals in a phase 2 study for an experimental lung disease drug. The medication, an inhaled hypertension treatment originally from Bayer, saw Roivant invest $14 million into the asset. This clinical success contributed to Roivant and another unnamed biotech stock reaching record highs. The drug's ability to meet mid-stage endpoints marks a successful turnaround for the Bayer-originated therapy.Why it mattersBiotech valuations often swing based on clinical trial data. Roivant's strategy involves acquiring assets from larger firms like Bayer to advance them thro